LAS VEGAS, NV--(Marketwired - Jan 12, 2015) - Alkame Holdings, Inc. (
Investor Awareness, Inc. will assist Alkame Holdings, Inc. in creating outreach programs to increase visibility in the investment community and in news dissemination to help broaden awareness.
The Company's Chief Executive Officer, Robert Eakle, said, "We look forward to working with Investor Awareness, Inc. to assist us in telling our story as we continue our focus on driving shareholder value by creating a first in class diversified holding company with multiple potential revenue streams. As a public entity, who expects significant growth, we are confident that Investor Awareness, Inc. will provide the level of expertise that can effectively bring an awareness of our Company to the financial markets."
Tony Schor, President of Investor Awareness, Inc., said, "We are pleased to work on behalf Alkame Holdings, Inc. during this exciting transformation to a holding company with diversified technologies and product offerings in the profitable water industry."
About Alkame Holdings, Inc. (ALKM)
Alkame Holdings, Inc. is a publicly traded health and technology holding company with a focus on patentable, innovative, and eco-friendly consumer products. The Company's wholly-owned subsidiary, Alkame Water, Inc., markets and distributes micro-clustered, alkaline, antioxidant and oxygenated bottled water utilizing an exclusive patented formula and technology. Alkame uses a patented technology that creates water with several unique properties which allow the body to absorb and utilize it more efficiently and help to achieve an optimal pH balance. The patented Alkame technology also increases the available oxygen content and absorbability which equates to more fuel for improved metabolic efficiency, boosted immune system, and improved cardio respiratory function.
Disclaimer/Safe Harbor: This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that Alkame will achieve significant sales, the failure to meet schedule or performance requirements of the Company's contracts, the Company's liquidity position, the Company's ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.